Investigating how early genetic changes affect prostate cancer progression and treatment resistance
Official title: The role of early oncogenic drivers in maintaining lineage fidelity in prostate cancer
Funded at Weill Medical Coll of Cornell Univ · NIH-11167102 · Data updated 2026-11-12
This study is looking at how certain early genetic changes in prostate cancer, especially in the SPOP gene, affect how the cancer grows and responds to treatment, and it involves analyzing samples from patients to find out why some cancers become resistant to therapy.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | June 1, 2025 |
| Project end | April 30, 2030 |
| Funding year | 2025 |
| Award (this year) | $683,979 |
| NIH project number | 1R01CA301637-01 |
| Project ID | NIH-11167102 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with prostate cancer, particularly those with early-stage disease or specific genetic mutations.
✕Less likely to help
Patients with advanced prostate cancer who do not have the relevant genetic mutations may not benefit from this research.
What this research studies
This research focuses on understanding the role of early genetic alterations in prostate cancer and how they influence the disease's progression and response to treatment. By examining specific mutations, particularly in the SPOP gene, the study aims to uncover mechanisms that maintain the cancer's lineage and contribute to resistance against therapies. Patients will be involved through the analysis of human prostate cancer samples, and novel models will be used to simulate disease progression. The ultimate goal is to identify distinct pathways that lead to treatment-resistant forms of prostate cancer.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment strategies for prostate cancer by targeting specific genetic alterations.
How similar studies have gone: Previous research has shown promising results in understanding genetic alterations in prostate cancer, suggesting that this approach could yield valuable insights.
Where this research is happening
-
Weill Medical Coll of Cornell Univ
New York, United States Active
Researchers
- Principal investigator: Barbieri, Christopher E — Weill Medical Coll of Cornell Univ
- Study coordinator: Barbieri, Christopher E
Related research
Other NIH-funded projects on the same topics.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
-
Characterizing epigenetic targets in prostate cancer to help AR-driven cancer
A research project at MD Anderson aims to understand how epigenetic factors shape androgen receptor signaling in prostate cancer to find new ways to treat resistant forms of the disease.
-
AR and RNA-binding in prostate cancer resistance
A cancer research grant exploring how the androgen receptor’s interaction with RNA may drive treatment resistance in prostate cancer, with potential to guide new therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.